CellaVision AB : CellaVision and Sysmex announce a jointly-developed product
for hematology labs
This information was released for public disclosure on April 16, 2013 at 3.00
CellaVision today announced that the company and its partner Sysmex have
co-developed a product which integrates CellaVision Digital Cell Morphology
technology with the Sysmex XN-series hematology platform. The product, DI-60,
will be part of the global Sysmex product portfolio for hematology
For the first time, digital cell morphology has been successfully integrated
with a cell counter and slide preparation device, eliminating the need to
manually load the slide for analysis, thus further streamlining the hematology
workflow and providing highest testing efficiency.
Since 2001, CellaVision has had a successful distribution arrangement with
Sysmex and together both parties created the market for digital microscopy
analysis. With this joint product development, Sysmex and CellaVision have
demonstrated a new level of excellence in cooperation.
The target market is primarily clinical laboratories with medium to large
sample volumes. With the DI-60 product Sysmex enhances their product portfolio
of digital cell morphology products, including the CellaVision DM96 and DM1200
systems. Similar to CellaVision's other products the DI-60 automates work
traditionally performed manually under a microscope. Test results are stored
digitally with images of blood cells and other patient information, increasing
the efficiency while improving the quality of the manual differential.
Sysmex plans to present the DI-60 for the first time at the trade fair IFCC
EUROMEDLAB 2013 in Milan, Italy, on May 19-23, 2013.
For more information please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708-33 77 82 | Email: email@example.com
CellaVision is an innovative, global medical technology company that develops
and sells its own leading systems for routine analysis of blood and other body
fluids in health care services. The products rationalize manual laboratory
work, and secure and support effective workflows and skills development within
and between hospitals. The company has leading-edge expertise in image
analysis, artificial intelligence and automated microscopy. In most countries
sales are via global partners. The products are sold directly in the Nordic
countries and via subsidiaries in the US, Canada and Japan. In 2012 sales were
SEK 170 million and sales continue to increase, with a growth target of at
least 15 % per year over an economic cycle. CellaVision's registered office is
in Lund, Sweden. The share is listed on the Nasdaq OMX Stockholm, Small Cap
list. Read more at www.cellavision.com.
About Sysmex Corporation
This information is disclosed by CellaVision AB (publ) pursuant to the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public disclosure on April 16, 2013 at 3.00 pm
Press release as PDF
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.